Sponsorship Link
Pfizer Inc. (NYSE: PFE) said it agreed to sell its Capsugel business, a maker of hard capsules, to private equity firm Kohlberg Kravis Robert & Co. for $2.375 billion in cash.
/
Related Articles
Search Senior Housing Facilities
Create a personal senior housing list with our search. Search Nursing Homes to find U.S. News-rated facilities. For other types of senior housing, you can access Seniors for Living's list of thousands of additional facilities.
Enter location
| or |
Selecting housing type
To reflect the sale, Pfizer reduced its 2011 reported revenue forecast range to $65.2 - $67.2 billion from $66.0 - $68.0 billion, and 2012 reported revenue target range to $62.2 - $64.7 billion from $63.0 – $65.5 billion.
Pfizer had said last year that it would review strategic alternatives for Capsugel that may include a sale. Pfizer said it would use the proceeds of the sale to to make additional repurchases of its common stock.
Capsugel generated about $750 million in revenue and manufactured more than 180 billion hard capsules in 2010, the New York drugmaker said.
Must Read
Henry Kravis and George Roberts, Co-Founders, Co-Chairmen and Co-CEOs of KKR, stated, "Capsugel has an excellent portfolio and outstanding reputation for providing high-quality, innovative drug-delivery solutions."
Follow us
The company said on Monday it expects the deal to close during the third quarter, assuming the receipt of the required regulatory clearances and satisfaction of other closing conditions.
Pfizer’s financial advisors for the transaction were Morgan Stanley & Co. Incorporated and Guggenheim Securities, LLC.
Shares of Pfizer ended Friday's regular trading at $20.38.
